ASND — Expected completion of clinical trial for TransCon CNP in Achondroplasia
Aug 1, 2025, 4:00:00 AM UTC
Summary
Ascendis Pharma A/S expects to complete a clinical trial for TransCon CNP, which aims to evaluate the efficacy and safety of the drug in children with Achondroplasia, on August 1, 2025. The trial, identified as NCT05598320, involves 84 participants aged 2 to 11 years and compares once weekly subcutaneous doses of 100 µg CNP/kg against a placebo. It includes a double-blind, placebo-controlled phase followed by an open-label extension. The results could inform further development of TransCon CNP, which targets a significant unmet need in treating Achondroplasia, a genetic growth disorder.
Company
ASCENDIS PHARMA A (ASND)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.ascendispharma.comSimilar Events
Expected Completion of Clinical Trial for TransCon CNP in Infants with Achondroplasia
Ascendis Pharma A/S is set to complete a Phase 2 clinical trial evaluating the safety and efficacy of TransCon CNP, a drug aimed at treating infants with Achondroplasia, by March 1, 2027. The trial, which is double-blind and randomized, will assess 100 μg CNP/kg administered once-weekly for 52 weeks to 72 participants under two years of age. The trial is currently in the recruiting phase, with a start date of January 23, 2024. TransCon CNP is designed to address the genetic condition of Achondroplasia, potentially advancing treatment options for affected infants.
Clinical Trial CompletionExpected Completion of Clinical Trial for CHS-388
The clinical trial for CHS-388, sponsored by Coherus Biosciences, Inc., is expected to complete on August 1, 2026. CHS-388, a monoclonal antibody targeting IL-27, is being evaluated in patients with advanced solid tumors through a multi-part study. The trial includes safety and efficacy assessments both as a monotherapy and in combination with other treatments like pembrolizumab and toripalimab, involving a total enrollment of 260 patients. This completion date may impact the company's progress in oncology treatments and potentially influence investor sentiment towards its future pipeline of therapies.
Clinical Trial CompletionExpected Completion of Clinical Trial for Navepegritide in Adolescents with Achondroplasia
Ascendis Pharma A/S expects to complete a clinical trial evaluating navepegritide, a drug for treating achondroplasia in adolescents, on January 1, 2027. The trial, designated NCT06732895, is currently recruiting participants aged 12 to 18. It aims to assess the efficacy and safety of once weekly subcutaneous doses of navepegritide at 100 μg/kg compared to a placebo over a 52-week period, with a primary measure of annualized growth velocity. The trial plans to enroll 24 participants in Phase 2 of development.
Clinical Trial CompletionExpected Completion of Clinical Trial for CHS-114
The clinical trial for CHS-114, sponsored by Coherus Biosciences, is anticipated to complete on May 1, 2027. This study aims to assess the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care treatments in participants with advanced or metastatic solid tumors. The trial is currently in the recruiting phase, with an enrollment target of 40 participants and is classified as a Phase 1 trial. According to the provided details, this event holds significance for investors monitoring advances in cancer treatment developments from Coherus Biosciences.
Expected Trial Completion